<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320060</url>
  </required_header>
  <id_info>
    <org_study_id>PYR-206</org_study_id>
    <nct_id>NCT00320060</nct_id>
  </id_info>
  <brief_title>Effect of Pyridorin in Patients With Diabetic Nephropathy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioStratum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioStratum</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of Pyridorin
      (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic
      kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date>January 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>128</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridorin (pyridoxamine dihydrochloride)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with
             type 1 or type 2 diabetes

          -  Sitting blood pressure of &lt;=170/100 mm Hg at weeks -2 and -1

          -  Hemoglobin A1C &lt;=12% at week -2

          -  Patients with diagnosis of diabetic nephropathy as defined by

               1. Serum Creatinine &lt;=2.0 mg/dL at weeks -2 and -1

               2. Urinary albumin excretion &gt;=300 mg/24 hours at week -2

               3. Diagnosis of diabetic retinopathy

          -  Creatinine clearance &gt;=40 mL/min at weeks -2 and -1

          -  Voluntary written consent to participate in this study

        Exclusion Criteria:

          -  History of allergic or adverse response to any B vitamin

          -  History of major cardiovascular or cerebrovascular events

          -  History of cancer except adequately treated basal or squamous cell carcinoma of the
             skin

          -  History of diabetic ketoacidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thorsten P Degenhardt, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>BioStratum, Inc.</affiliation>
  </overall_official>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 27, 2006</last_update_submitted>
  <last_update_submitted_qc>April 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2006</last_update_posted>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Advanced Glycation Endproduct Inhibitor</keyword>
  <keyword>Pyridorin</keyword>
  <keyword>Pyridoxamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

